Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Moderate-to-Severe Atopic Dermatitis
CTR20201120Phase 2Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in atopic dermatitis (AD), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Sep 2020; status: completed.
02
Drugs
jaktinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20201120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201120.